Strong Ph II safety data on Generex breast cancer vaccine
A breast cancer vaccine currently being tested in a Phase II trial is safe and well tolerated in patients, according to a paper to be published in an upcoming issue of the Journal of Clinical Oncology.
USA-based Generex' AE37 uses a peptide antigen (immune-stimulating fragment) of a cancer gene known as HER-2/neu, which is present in many types of cells but is over-expressed in a high proportion of breast cancers as well as many others.
The AE37 vaccine is based on one of two proprietary platform technologies established at Antigen Express, a unit of Generex. The technology helps the body fight cancer by modifying fragments of cancer-associated antigens to increase their potency in stimulating the immune system, while also leaving an imprint to fight cancer should it ever reoccur.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze